“Pain is inevitable, suffering is optional.” — Popular proverb I once slipped on black ice at the end of our street. My handbag, its contents, and my cellphone flew just outside of arm’s reach. I could see our home while I lay on the cold and dirty city sidewalk. Maybe…
treatment
Rituximab may be a more effective immunosuppressive therapy for preventing a first relapse in people with neuromyelitis optica spectrum disorder (NMOSD) than mycophenolate mofetil (MMF), a new meta-analysis found. The anti-CD20 antibody rituximab, commonly used off-label in NMOSD, also appears to work better than azathioprine, though the results failed…
Merck KGaA will continue to advance CRD1 for the treatment of neuromyelitis optica spectrum disorder (NMOSD) and generalized myasthenia gravis (gMG), after the company acquired the therapy’s original developer, Chord Therapeutics. The investigational therapy is an oral cladribine product that works by reducing the number of immune cells, namely…
Uplizna (inebilizumab-cdon), a medication for the treatment of neuromyelitis optica spectrum disorder (NMOSD), is now available in the U.S. through specialty distributor BioCareSD and specialty infusion pharmacy BioTek Remedys. The companies added the medication to their portfolio of specialty therapeutics to expand upon their product offering…
Uplizna (inebilizumab-cdon) safely prevented autoimmune attacks in 83% of people with neuromyelitis optica spectrum disorder (NMOSD) who received the treatment for four or more years, data from the N-MOmentum Phase 2/3 clinical trial show. Among those who experienced relapses, most did so during the first year of treatment.
As someone with neuromyelitis optica (NMO), I am no stranger to steroids. Like most NMO patients, I have a love-hate relationship with them. I jokingly refer to them as “the devil’s Tic Tacs” because of the potential side effects, many of which can be quite serious. On the flip side,…
Treatment with Horizon Therapeutics’ Uplizna (inebilizumab) leads to a rapid and sustained drop in immune B-cells in adults with neuromyelitis optica spectrum disorder (NMOSD), data from the N-MOmentum Phase 2/3 clinical trial show. Notably, while all Uplizna-treated patients experienced significant clinical benefits, those with greater B-cell depletion showed lower…
Treatment with Horizon Therapeutics’ Uplizna (inebilizumab-cdon) was found safe and effective at reducing the frequency of attacks in African-American adults with neuromyelitis optica spectrum disorder (NMOSD), according to a retrospective analysis of the N-MOmentum clinical trial. These findings were presented in a poster at the 15th World Congress…
Tests, treatments, and medical procedures are important, but they can be a hassle and are sometimes painful. I don’t always know what to expect, which creates anxiety, especially if a needle is involved. As a neuromyelitis optica (NMO) patient, I have had bloodwork, MRIs, and spinal taps, and I…
COVID-19 vaccines are safe and well-tolerated by people with the rare neurological disorders neuromyelitis optica spectrum disorder (NMOSD), MOG-antibody disease (MOGAD), and transverse myelitis in the U.S., according to a recent study. Patients surveyed about their vaccine experiences reported a rate of side effects similar to that of the…
Recent Posts
- New antibody may explain mystery cases of NMOSD-like disease
- Are those mystery aches and pains due to NMOSD or regular life?
- NMOSD therapy linked to fewer attacks, less disability in Chinese study
- Where I go to recharge from the daily challenges of NMOSD
- Clinical trial data show NMOSD treatment reduces relapses